Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

SAN DIEGO, May 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We achieved a significant milestone in the first quarter with the European regulatory filing of the subcutaneous Herceptin program by our partner Roche," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "Despite the HyQ regulatory delay from our Baxter collaboration, our pipeline has continued to make tangible progress on all fronts, as well as across diverse therapeutic areas and geographies."

First Quarter Highlights Highlights of Halozyme's first quarter activities and recent events include:

  • Notification from the European Patent Office (EPO) that a hearing scheduled in opposition of the European patent for Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) was cancelled and the EPO acknowledged the patentability of the claims. The Company anticipates the EPO to issue a final written decision to this effect.
  • Announced with our collaborator, Baxter, that the U.S. Food and Drug Administration (FDA) requested additional information to complete its review of the HyQ Biologics License Application (BLA).The Companies will work together to develop studies to provide additional data to address the concerns raised by the agency.
  • In addition to filing a Line Extension Application for subcutaneous (SC) Herceptin® (trastuzumab) with the European Medicines Agency (EMA), Roche presented Phase 3 registration data from the HannaH trial at the Early Breast Cancer Conference in Vienna. The study met its co-primary endpoints of pharmacokinetics and efficacy. Herceptin SC, using rHuPH20, may provide gre
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
    (Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
    (Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
    Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
    ... a leading Clinical Research Organization, announces it is ... World (ECDW), 13-14 May 2009, in London, UK. ... and most highly regarded early development congress. Experts ... be available to discuss PRA,s capabilities at ECDW. ...
    ... 11 Arno Therapeutics, Inc., a clinical-stage biopharmaceutical ... the U.S. Food and Drug Administration ("FDA") accepted ... the use of AR-12, a potentially first-in-class, orally ... and induces the endoplasmic reticulum stress pathway. ...
    Cached Medicine Technology:PRA International: Participating Sponsor for Exploratory Clinical Development World in London 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 3
    (Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
    (Date:7/13/2014)... 2014 According to The Peripheral Neuropathy ... comprehensive program that teaches people how to deal with ... without medications. This program also provides people with safe ... neuropathy , including numbness, prickling, burning, and intense stabbing ... this home treatment program can help people eliminate some ...
    (Date:7/12/2014)... 2014 Recently, iFitDress.com, one of the world’s ... red evening gowns . What’s more, all these hot ... , The company’s senior spokesman states, “We are proud to ... website is an enjoyable shopping experience. In addition to the ... store, low prices do not always mean bad quality. All ...
    (Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
    (Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
    Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
    ... Stiefel Laboratories, Inc.,("Stiefel Laboratories"), the world,s ... today that the waiting,period under the Hart-Scott-Rodino ... Act") has expired, for its proposed acquisition ... BTRX )., As previously announced, Stiefel ...
    ... of Adelaide have developed a novel approach to treating ... fewer side effects. , Professor Wayne Tilley and Dr ... Research Laboratories have discovered that by using existing prostate ... doses, they can expect to generate better results for ...
    ... smoking spouse quits , , TUESDAY, July 29 (HealthDay News) -- ... risk for experiencing a stroke, a new study suggests. , ... who still smoke carry an even greater risk for stroke. ... bear any higher risk for stroke than those married to ...
    ... Southern Home Medical,Equipment, Inc. (OTC: SHOM) announced today ... solid growth. Industry statistics,suggest a very favorable market ... from the U.S. Bureau of Labor Statistics published ... one million new and,replacement nurses will be needed ...
    ... for Excellence Issue Brief, WASHINGTON, July 29 ... has issued its second issue brief on retiree,health ... Estimates,of Liabilities. The brief, which was written by ... and entrepreneurship in the,College of Management, North Carolina ...
    ... single women identify any gaps in coverage or inadequate protection ... ... 2008 -- http://www.combinedinsurance.com/ [Combined Insurance], a leading provider ... 27-August 2, 2008, sponsored by SWWAN® (Single Working Women,s Affiliate ...
    Cached Medicine News:Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 2Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 3Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 4Health News:New treatment for advanced prostate cancer 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3Health News:Southern Home Medical's Encore Medical Staffing Division Poised to Benefit from Major Growth in Nursing Industry 2Health News:Financing Retiree Health Care: Assessing GASB 45 Estimates of Liabilities 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 3Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 4Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 5
    ... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
    ... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
    ... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
    Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
    Medicine Products: